Treatment with anti-inflammatory drugs in community-acquired pneumonia

Journal of Internal Medicine

Volumn 272, Issue 1, 2012, Pages 25-35

  Meijvis, S C A ^a   van de Garde, E M W ^a,b   Rijkers, G T ^a,c   Bos, W J W ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Roosevelt Academy   (Netherlands)

Author keywords

Anti inflammatory treatment; Pneumonia

Indexed keywords

ANTIINFLAMMATORY AGENT; CORTICOSTEROID; DEXAMETHASONE; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; METHYLPREDNISOLONE; PREDNISOLONE; TOLL LIKE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; COMMUNITY ACQUIRED PNEUMONIA; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INCIDENCE; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; AGE FACTORS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BACTEREMIA; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; DRUG RESISTANCE, BACTERIAL; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MACROLIDES; NETHERLANDS; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TOLL-LIKE RECEPTORS;

EID: 84862663670     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2012.02554.x     Document Type: Review

References (79)

1. Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134-41.
2. Antunes G, Evans SA, Lordan JL, Frew AJ. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J 2002; 20: 990-5.
3. Fernandez-Serrano S, Dorca J, Coromines M, Carratala J, Gudiol F, Manresa F. Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol 2003; 10: 813-20.
4. Padrones S, Garcia-Vidal C, Fernandez-Serrano S et al. Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2010; 29: 1243-51.
5. Buonsenso D, Serranti D, Valentini P. Management of central nervous system tuberculosis in children: light and shade. Eur Rev Med Pharmacol Sci 2010; 14: 845-53.
6. Brouwer MC, McIntyre P, de Gans J, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2010; Issue 9: CD004405.
7. Thwaites GE, Bhavnani SM, Chau TT et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother 2011; 55: 3244-53.
8. Odio CM, Ramirez T, Arias G et al. Double blind, randomized, placebo-controlled study of dexamethasone therapy for hematogenous septic arthritis in children. Pediatr Infect Dis J 2003; 22: 883-8.
9. Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34: 17-60.
10. Amsden GW. Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55: 10-21.
11. Cohen ML. Changing patterns of infectious disease. Nature 2000; 406: 762-7.
12. Fauci AS, Morens DM. The perpetual challenge of infectious diseases. N Engl J Med 2012; 366: 454-61.
13. Ginsburg I. The role of bacteriolysis in the pathophysiology of inflammation, infection and post-infectious sequelae. APMIS 2002; 110: 753-70.
14. Chaplin DD. Overview of the immune response. J Allergy Clin Immunol 2010; 125: S3-23.
15. Parkin J, Cohen B. An overview of the immune system. Lancet 2001; 357: 1777-89.
16. Kelso A. Cytokines and their receptors: an overview. Ther Drug Monit 2000; 22: 40-3.
17. Schaaf BM, Boehmke F, Esnaashari H et al. Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. Am J Respir Crit Care Med 2003; 168: 476-80.
18. Takashima K, Tateda K, Matsumoto T, Iizawa Y, Nakao M, Yamaguchi K. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect Immun 1997; 65: 257-60.
19. van der Poll T., de Waal MR, Coyle SM, Lowry SF. Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis 1997; 175: 118-22.
20. Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344: 1140-4.
21. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344: 1058-66.
22. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-23.
23. Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008; 4: 525-33.
24. Galon J, Franchimont D, Hiroi N et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 2002; 16: 61-71.
25. Franchimont D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann N Y Acad Sci 2004; 1024: 124-37.
26. Annane D, Sebille V, Charpentier C et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-71.
27. Annane D, Bellissant E, Bollaert PE et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009; 301: 2362-75.
28. Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest 1993; 104: 389-92.
29. Niewoehner DE, Erbland ML, Deupree RH et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340: 1941-7.
30. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456-60.
31. Garcia-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 2007; 30: 951-6.
32. Mikami K, Suzuki M, Kitagawa H et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007; 185: 249-55.
33. Confalonieri M, Urbino R, Potena A et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171: 242-8.
34. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010; 181: 975-82.
35. Fernandez-Serrano S, Dorca J, Garcia-Vidal C et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care 2011; 15: R96.
36. Meijvis SC, Hardeman H, Remmelts HH et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377: 2023-30.
37. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292: 1160-4.
38. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-402.
39. Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J. The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care 2010; 25: 656.e7-22.
40. Novack V, Eisinger M, Frenkel A et al. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med 2009; 35: 1255-60.
41. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781-90.
42. van den Hoek HL, Bos WJ, de Boer A, van de Garde EM. Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials. BMJ 2011; 343: d7281.
43. Kruger PS, Harward ML, Jones MA et al. Continuation of statin therapy in patients with presumed infection: a randomized controlled trial. Am J Respir Crit Care Med 2011; 183: 774-81.
44. Perry TW, Pugh MJ, Waterer GW et al. Incidence of cardiovascular events after hospital admission for pneumonia. Am J Med 2011; 124: 244-51.
45. Bruns AH, Oosterheert JJ, Cucciolillo MC et al. Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia compared with the general Dutch population. Clin Microbiol Infect 2010; doi: 10.1111/j.1198-743X.2010.03296.x. [Epub ahead of print].
46. www.clinicaltrials.gov Pravastatin and Ventilatory Associated Pneumonia NCT00702130. 2012.
47. www.clinicaltrials.gov STATINs and Ventilator-Associated Pneumonia NCT01057758. 2012.
48. Yang M, Dong BR, Lu J, Lin X, Wu HM. Macrolides for diffuse panbronchiolitis. Cochrane Database Syst Rev 2010; Issue 12: CD007716.
49. Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2011; 12: CD002203.
50. Kostadima E, Tsiodras S, Alexopoulos EI et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J 2004; 23: 714-7.
51. Kovaleva A, Remmelts HH, Rijkers GT, Hoepelman AI, Biesma DH, Oosterheert JJ. Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review. J Antimicrob Chemother 2012; 67: 530-40.
52. Duong M, Simard M, Bergeron Y, Bergeron MG. Kinetic study of the inflammatory response in Streptococcus pneumoniae experimental pneumonia treated with the ketolide HMR 3004. Antimicrob Agents Chemother 2001; 45: 252-62.
53. Hardy RD, Rios AM, Chavez-Bueno S et al. Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia. Antimicrob Agents Chemother 2003; 47: 1614-20.
54. Rios AM, Mejias A, Chavez-Bueno S et al. Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection. Antimicrob Agents Chemother 2004; 48: 2897-904.
55. Rios AM, Fonseca-Aten M, Mejias A et al. Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother 2005; 49: 3970-3.
56. Demartini G, Esposti D, Marthyn P, Lapidari A, Fraschini F, Scaglione F. Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFNgamma and IL-10 plasma levels in patients with community acquired pneumonia. J Chemother 2004; 16: 82-5.
57. Yasuda Y, Kasahara K, Mizuno F, Nishi K, Mikasa K, Kita E. Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model. Antimicrob Agents Chemother 2007; 51: 1741-52.
58. Khair OA, Devalia JL, Abdelaziz MM, Sapsford RJ, Davies RJ. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J 1995; 8: 1451-7.
59. van Langevelde P, Ravensbergen E, Grashoff P, Beekhuizen H, Groeneveld PH, van Dissel JT. Antibiotic-induced cell wall fragments of Staphylococcus aureus increase endothelial chemokine secretion and adhesiveness for granulocytes. Antimicrob Agents Chemother 1999; 43: 2984-9.
60. Lin E, Stanek RJ, Mufson MA. Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro. Antimicrob Agents Chemother 2003; 47: 1151-3.
61. Baddour LM, Yu VL, Klugman KP et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170: 440-4.
62. Martinez JA, Horcajada JP, Almela M et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 389-95.
63. Mufson MA, Stanek RJ. Revisiting combination antibiotic therapy for community-acquired invasive Streptococcus pneumoniae pneumonia. Clin Infect Dis 2006; 42: 304-6.
64. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161: 1837-42.
65. Weiss K, Low DE, Cortes L et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004; 11: 589-93.
66. Aspa J, Rajas O, Rodriguez de CF et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006; 27: 1010-9.
67. Dwyer R, Ortqvist A, Aufwerber E et al. Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2006; 25: 518-21.
68. Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009; 33: 153-9.
69. Martin-Loeches I, Lisboa T, Rodriguez A et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010; 36: 612-20.
70. Anas AA, Wiersinga WJ, de Vos AF, van der Poll T. Recent insights into the pathogenesis of bacterial sepsis. Neth J Med 2010; 68: 147-52.
71. Gao H, Leaver SK, Burke-Gaffney A, Finney SJ. Severe sepsis and Toll-like receptors. Semin Immunopathol 2008; 30: 29-40.
72. Tsujimoto H, Ono S, Efron PA, Scumpia PO, Moldawer LL, Mochizuki H. Role of Toll-like receptors in the development of sepsis. Shock 2008; 29: 315-21.
73. Munoz N, Van Maele L, Marques JM, Rial A, Sirard JC, Chabalgoity JA. Mucosal administration of flagellin protects mice from Streptococcus pneumoniae lung infection. Infect Immun 2010; 78: 4226-33.
74. Karlstrom A, Heston SM, Boyd KL, Tuomanen EI, McCullers JA. Toll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza. J Infect Dis 2011; 204: 1358-66.
75. Moens L, Verhaegen J, Pierik M et al. Toll-like receptor 2 and Toll-like receptor 4 polymorphisms in invasive pneumococcal disease. Microbes Infect 2007; 9: 15-20.
76. Yuan FF, Marks K, Wong M et al. Clinical relevance of TLR2, TLR4, CD14 and FcgammaRIIA gene polymorphisms in Streptococcus pneumoniae infection. Immunol Cell Biol 2008; 86: 268-70.
77. Rice TW, Wheeler AP, Bernard GR et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 2010; 38: 1685-94.
78. Xu F, Droemann D, Rupp J et al. Modulation of the inflammatory response to Streptococcus pneumoniae in a model of acute lung tissue infection. Am J Respir Cell Mol Biol 2008; 39: 522-9.
79. RIVM Nationaal kompas volksgezondheid. Accessed 20 April 2011.